title: Cisapride for constipation in spinal cord injured patients: a preliminary report.
abstract: Chronic constipation in patients with spinal cord injury (SCI) has significant impact on quality of life. To measure baseline clinical functioning, colonic transit time and anorectal manometry and the effect of cisapride on these clinical and physiological parameters, we studied 12 SCI patients. Patients initially received baseline clinical scoring, measurement of colonic transit time and anorectal manometry. Patients then received cisapride 20 mg orally three times each day. After one and three months of cisapride therapy, all measurements were repeated. The mean duration cisapride treatment was 5.2 months. Six of 12 (50 percent) reported that symptoms of constipation improved. No patient had worsening of symptoms. Prior to cisapride treatment, 23 percent of patients passed colonic transit markers by day five and 57 percent by day seven; baseline anal manometry revealed variable resting and squeeze pressures. After treatment, 33 percent of patients passed their colonic transit markers by day five and 71 percent by day seven. Six of 12 (50 percent) demonstrated a 10 percent or more increase in resting anal canal pressures. We conclude that about 50 percent of SCI patients have subjective improvement in constipation after cisapride therapy. Cisapride appears to improve both colonic and anorectal function.
authors.affiliation: St Louis University School of Medicine, Department of Surgery, Missouri, USA.
authors.forename: W E
authors.initials: WE
authors.lastname: Longo
authors.forename: R M
authors.initials: RM
authors.lastname: Woolsey
authors.forename: A M
authors.initials: AM
authors.lastname: Vernava
authors.forename: K S
authors.initials: KS
authors.lastname: Virgo
authors.forename: L
authors.initials: L
authors.lastname: McKirgan
authors.forename: F E
authors.initials: FE
authors.lastname: Johnson
mesh_terms: D020117:Cisapride; D003125:Colostomy; D003248:Constipation / Q000188:drug therapy*; D005769:Gastrointestinal Motility / Q000187:drug effects; D005772:Gastrointestinal Transit / Q000187:drug effects; D006801:Humans; D008365:Manometry; D010264:Paraplegia / Q000188:drug therapy; D010277:Parasympathomimetics / Q000009:adverse effects / Q000627:therapeutic use*; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D011782:Quadriplegia / Q000188:drug therapy; D013119:Spinal Cord Injuries / Q000188:drug therapy*
chemical_list: D010277:Parasympathomimetics; D010880:Piperidines; D020117:Cisapride